

Incidence and characteristics of adverse events in paediatric inpatient care: a systematic review and meta-analysis

Pernilla Dillner ⁽¹⁾, ^{1,2} Luisa C Eggenschwiler ⁽¹⁾, ³ Anne W S Rutjes ⁽¹⁾, ^{4,5} Lena Berg ⁽¹⁾, ^{6,7} Sarah N Musy ⁽¹⁾, ³ Michael Simon ⁽¹⁾, ³ Giusi Moffa ⁽¹⁾, ⁸ Ulrika Förberg ⁽¹⁾, ^{1,6} Maria Unbeck ⁽¹⁾, ^{6,9}

ABSTRACT

Background Adverse events (AEs) cause suffering for hospitalised children, a fragile patient group where the delivery of adequate timely care is of great importance. **Objective** To report the incidence and characteristics of AEs, in paediatric inpatient care, as detected with the Global Trigger Tool (GTT), the Trigger Tool (TT) or the Harvard Medical Practice Study (HMPS) method.

Method MEDLINE, Embase, Web of Science and Google Scholar were searched from inception to June 2021, without language restrictions. Studies using manual record review were included if paediatric data were reported separately. We excluded studies reporting: AEs for a specific disease/ diagnosis/treatment/procedure, or deceased patients: study protocols with no AE outcomes: conference abstracts. editorials and systematic reviews: clinical incident reports as the primary data source: and studies focusing on specific AEs only. Methodological risk of bias was assessed using a tool based on the Quality Assessment Tool for Diagnostic Accuracy Studies 2. Primary outcome was the percentage of admissions with \geq 1 AEs. All statistical analyses were stratified by record review methodology (GTT/TT or HMPS) and by type of population. Meta-analyses, applying randomeffects models, were carried out. The variability of the pooled estimates was characterised by 95% prediction intervals (Pls).

Results We included 32 studies from 44 publications, conducted in 15 countries totalling 33 873 paediatric admissions. The total number of AEs identified was 8577. The most common types of AEs were nosocomial infections (range, 6.8%–59.6%) for the general care population and pulmonary-related (10.5%–36.7%) for intensive care. The reported incidence rates were highly heterogeneous. The PIs for the primary outcome were 3.8%-53.8% and 6.9%-91.6% for GTT/TT studies (general and intensive care population). The equivalent PI was 0.3%-33.7% for HMPS studies (general care). The PIs for preventable AEs were 7.4%-96.2% and 4.5%-98.9% for GTT/TT studies (general and intensive care population) and 10.4%-91.8% for HMPS studies (general care). The guality assessment indicated several methodological concerns regarding the included studies.

Conclusion The reported incidence of AEs is highly variable in paediatric inpatient care research, and it is not possible to estimate a reliable single rate. Poor reporting standards and methodological differences hinder the comparison of study results.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ The only available systematic review in this area is dated and shows a surprisingly low estimate of adverse event (AE) incidence. As paediatric inpatients are particularly vulnerable and run a high risk of exposure to AEs, a systematic review examining this important knowledge gap is lacking.

WHAT THIS STUDY ADDS

⇒ This review gives an up-to-date estimate of the incidence and variation of paediatric inpatient AEs. It also adds relevant methodological reflections about structured retrospective record review methods, as well as their application and reporting quality.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ A better knowledge of the complex nature of paediatric AEs is important for the development of more targeted patient safety interventions to increase quality of care and prevent paediatric patients suffering AEs. An awareness of the current incomplete reporting of key elements related to AE data may help researchers to improve the quality of reporting in future studies.

INTRODUCTION

Adverse events (AEs) are costly,¹ cause suffering for patients, their families and for healthcare professionals² and have been recognised as a critical global healthcare issue.^{3 4} An AE may be defined as unintended physical injury

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bmjqs-2022-015298).

For numbered affiliations see end of article.

Correspondence to

Pernilla Dillner, Department of Women's and Children's Health, Karolinska Institutet, Stockholm 171 77, Sweden; pernilla.dillner@ki.se

PD and LCE are joint first authors.

Received 23 June 2022 Accepted 8 November 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Dillner P, Eggenschwiler LC, Rutjes AWS, et al. BMJ Qual Saf Epub ahead of print: [please include Day Month Year]. doi:10.1136/ bmjqs-2022-015298





resulting from or contributed to by medical care that requires additional monitoring, treatment or hospitalisation, or that results in death.⁵ The incidence of AEs varies between contexts (eg, country, hospital types, included specialities) and research is heavily influenced by the method used. Between 7% and 40% adult general inpatients are affected by AEs. These are often deemed to be preventable, indicating that patient safety can be improved.⁶

Hospitalised children are a fragile patient group. Even a low degree of error related to acts of omissions or commissions can affect the child's health and in the long-term risk affecting the child's development and future.⁷ Patients treated at intensive care units run a greater risk of being exposed to AEs than general care patients.^{8 9} Sedation and the need for intravascular and/or breathing devices are factors associated with AEs in paediatric patients. Those patients experiencing AEs are on average younger and have a longer length of stay.⁸

There are various methods for detecting, measuring and characterising AEs in healthcare, but as yet no gold standard exists.¹⁰ A commonly used method is structured retrospective record review, which includes different approaches, for example, the Harvard Medical Practice Study (HMPS) method^{11 12} or the Global Trigger Tool (GTT)⁵ with its subsequent adaptations (Trigger Tools, TTs) to be used in different contexts, such as paediatrics,^{13 14} oncology,¹⁵ psychiatry¹⁶ or home healthcare.¹⁷ Record review has been shown to be superior in detecting AEs compared with other methods, such as incident reporting systems and administrative data.^{14 18-20}

In adult care, several systematic reviews⁶ ²¹⁻²⁴ regarding the identification of AEs using record review methodology, with or without meta-analysis, have been published. To the best of our knowledge, only one systematic review focusing on paediatric care has been published.²⁵ This review included nine publications, of which six used record review data and three used administrative record data, and was restricted to a minimum of 1000 patients. The admission year for included patients ranged from 1984 to 2009. This review presents a surprisingly low AE incidence. The publications of GTT and TT studies in the paediatric context have increased in the last 10 years. Therefore, an updated systematic review, irrespective of study sample sizes, was indicated. The aim of this systematic review is to report the incidence and characteristics of AEs, in paediatric inpatient care, as detected with the GTT, the TT or the HMPS method.

METHODS

The review was carried out as a systematic review and meta-analysis. The study protocol was uploaded on h 10.5281/zenodo.5513354.

Information sources and search strategies

The following databases were used for the search: MEDLINE, Embase, Web of Science and Google Scholar.²⁶ A search strategy was developed with the help of librarians, and this encompassed subject headings and free text words that described the population, the context, the concept and type of evidence source. The search terms used were: Iatrogenic Disease, Medical Errors, Patient Harm, adverse event*, harm, trigger*, Adolescent, Child, Infant, p?ediatric*, neonat*, child*, newborn* infant*, adolescen*, premature*, preschool, teenager*, Hospitals, Inpatients, Hospitalisation, Hospital Units, Hospital Departments, hospital*, intensive care, inpatient*, review*, record*, chart*, trigger tool and Harvard Medical Practice*. The systematic searches were performed between 4 and 8 June 2021 and no restrictions in language or publication year were applied. The full search strategy and outcomes for the respective database are shown in online supplemental material 1, tables S1-S4. Furthermore, the search was supplemented in the data extraction process with a manual scan of the reference lists of eligible publications.

Selection process

Publications that met the following criteria were included: (1) Children, all age groups, if cared for in paediatric inpatient units; (2) Studies including both adults and paediatric patients if the data for paediatric patients were reported separately; (3) Peer reviewed full text primary publications, reporting relevant quantitative outcome data; (4) Studies applying manual retrospective medical record review using GTT, TT or HMPS methodologies. We accepted all types of AE definitions (online supplemental material 1, table S5).

The following exclusion criteria were applied: (1) Publications reporting AEs for paediatric patients with a specific disease/diagnosis/treatment/procedure or who were deceased; (2) Studies in primary care, psychiatric care, day care/ambulatory care and emergency departments or other outpatient units at the hospital; (3) Study protocols without AE outcome data; (4) Publications such as conference abstracts, editorials and systematic reviews; (5) Studies using, for example, clinical incident reporting systems as the primary data source where these incident reports were subsequently analysed using record review; and (6) Publications reporting only specific AEs, for example, adverse drug events (online supplemental material 1, table S5).

The first screening step of applying the eligibility criteria to titles and abstracts was done independently by four reviewers, working in pairs (MU/PD, UF/ LB). Thereafter, eligible full texts were retrieved, and the same reviewers independently assessed full texts. The reason for exclusion was noted and any discrepancies between the individual reviewers were discussed in the pairs until consensus was reached. If required, discussion was held with the whole research group. Discussions during the selection process mostly concerned whether multiple publications on the same study were considered as overlapping or not.

Data extraction process

To ensure quality, data were independently extracted by two researchers per publication. Data regarding key study characteristics (eg, sample size, setting, number of hospitals, method used, patient demographics) and patient outcomes (incidence, frequencies, preventability, types, severity) were collected. Authors of 27 primary studies were contacted by email to request additional information to calculate the primary outcome or part of the secondary outcomes. Information was provided from 17 studies. Any discrepancies between reviewers were resolved in the same way as in the selection process and a consensus for each study was reached. All the studies included were discussed at some point within the research group. Discussions were either related to the quality assessment, the methodology or interpretation of data.

Quality assessment

To assess the methodological quality of each included study, a previously used quality assessment tool (QAT) was adapted. This QAT was based on the structure of the Quality Assessment Tool for Diagnostic Accuracy Studies 2 tool²⁷ and the content of the QAT by Musy *et* al^{28} and later by Eggenschwiler *et al*²⁹ (online supplemental material 1, page 14). The QAT consists of five domains: patient selection, reviewers, record review process, outcomes and flow. Each domain includes two to three signalling questions which form the basis for the assessment of risk of bias and applicabilityrelated concerns. These were rated as either low, high or unclear. Expert knowledge in quality assessments and record review methodology guided the adaptations. Examples of adaptations used were revisions of the domain record review process with signalling questions regarding support and monitoring during the review process. Furthermore, the risk of bias and applicability-related concerns were also rated as an overall judgement for each study (online supplemental material 2). The QAT for each study was used by two reviewers independently and a consensus was reached.

Primary outcome

A meta-analysis was carried out with the percentage of admissions with ≥ 1 AEs as the primary outcome measure.

Secondary outcomes

Secondary outcomes were AEs per 100 admissions, AEs per 1000 inpatient days, percentage of preventable AEs, as well as percentage of admissions with preventable AEs. In addition, types of AEs and AE severity were described.

Statistical analysis

Analyses were conducted using R V.4.1.3 on Linux³⁰ with the meta³¹ and metafor³² packages. All statistical analyses were stratified, distinguishing general and intensive care populations, as these are known from the literature to differ in the distribution of AEs.⁶ ²² ³³ They were also stratified by the record review methodology used (GTT/TT or HMPS). The categorisation of the two populations was based on whether most patients were admitted to either general or intensive care units. Studies using the HMPS methodology did not predominantly include intensive care patients. The GTT and TT methodologies were analysed together, as these methods share the same conceptual approach.

Systematic review

Where not explicitly reported, we calculated the number of admissions with ≥ 1 AE from the reported percentage estimates of admissions with AEs. Similarly, we derived the number of patient days by dividing the total number of AEs by the reported rate of AEs per 1000 patient days. Studies using the HMPS methodology were excluded from the meta-analyses for AEs per 100 admissions and AEs per 1000 patient days. Most of these studies included only the most severe AE per admission and therefore the estimates were not comparable.

We fitted random intercept logistic models, using the R metaprop function with the Wilson method for CIs for the meta-analysis of the percentage of admissions with ≥ 1 AE, the percentage of preventable AEs and the percentage of admissions with preventable AEs.³¹ For the AEs per 100 admissions and AEs per 1000 patient days we used random intercept Poisson models, fitted with the R metarate function.³²

Other systematic reviews on the same topic reported I^2 values of up to 100%^{20 21 23}. Although frequently reported I² is not valid in the context of single proportions. We decided to characterise the variability of the estimates by reporting prediction intervals (PIs).^{34 35} The 95% PI quantifies the sample variability and is expected to capture estimates from future studies with a 95% level of confidence.³⁶ We identified high heterogeneity, illustrated by the width of the PIs, which is wider than the 95% CI in the presence of between-study heterogeneity. Hence, we focused our reporting on PIs rather than CIs. Furthermore, we investigated heterogeneity via stratified analyses of five elements relating to risk of bias and four connected to applicability-related concerns. P values, derived from the likelihood ratio test for model fit, were considered statistically significant with a value of p < 0.05. The PRISMA 2020 guideline for reporting systematic reviews was applied.³

RESULTS

Publication retrieval

The database searches yielded 3790 publications of which 1317 were duplicates leaving 2473 unique publications which were screened by title and

abstract. In total, 108 publications underwent full text screening, including four publications from reference lists. After assessment of eligibility, 64 publications were excluded and 44 publications⁸ ¹¹⁻¹⁴ ³³ ³⁸⁻⁷⁵ of 32 unique studies⁸ ¹¹ ¹² ¹⁴ ³³ ³⁸⁻⁴² ⁴⁵ ⁴⁸⁻⁵⁰ ⁵³ ⁵⁵ ⁵⁷⁻⁶⁸ ⁷¹⁻⁷⁴ were included (online supplemental material 1, figure S1). As one study⁵⁵ reported outcomes for both populations, a total of 33 samples were included, 22 for the general care and 11 for intensive care populations.

Study characteristics

The studies were published between 1991 and 2021 with inclusion periods ranging from year 1984 to 2019 and 59.4% of the studies were published in the last 10 years. The study periods ranged from 1 month to 6 years. The 32 studies originated from 15 countries, of which 34.4% were from North America, 28.1% from Europe, 18.8% from South America, 9.4% from Australia, 6.3% from Africa and 3.1% from Asia. In total, 33 873 paediatric admissions (median, 330; range: 11-6661) and 124 800 patient days (median, 2743; range, 87-21 789) were included. A wide variation of units was found, and 68.8% (n=22) of the 33 samples included mainly general care (eg, surgical, medical) and 34.4% (n=11) included mainly intensive care units for paediatric and neonatal patients. Patients' mean age (n=14 studies) varied between 3.0 years to 7.8 years and mean length of stay (n=17 studies) 2.8 days to 22.8 days (table 1). Most of the studies (n=28)were written in English, three in Spanish and one in Portuguese.

Study methodology characteristics

A majority used GTT/TT (n=23, 71.9 %), followed by HMPS (n=9, 28.1%). No study published after 2014 used the HPMS method. The most frequent sampling strategy was random (n=26, 81.3%). A majority of the 32 studies (n=25, 78.1%) were assessed to have used a two-stage retrospective record review process and the number of triggers/screening criteria varied between 14 and 88. Twenty-six (81.3%) described training prior to the review process (table 2) and 12 studies used test records.

Seven studies (21.9%) had teams where the whole or part of the team had prior experience in record review methodology and seven studies (21.9%) reported support during the review process, such as expert consultation. Ten studies (31.3%) described a monitoring process to ensure completeness, consistency and accuracy (data not shown).

Both acts of omissions and commissions were included in 53.1% (n=17) of the studies and 78.1% (n=25) included \geq 1AE per patient. Outcomes for inter-rater reliability, using double reviews, were reported in 53.1% (n=17). Of those, kappa values were reported in five (26.3%) studies, percentage agreement in four (21.1%), and both measures in eight (42.1%). Half of the studies included AE(s) that occurred both before, during and after index admission, and eight studies (25.0%) didn't specify the time frame for inclusion. The GTT manual's AE definition or similar was used in 17 studies (53.1%) and the HMPS definition or similar in 10 (31.3%) (table 2), and 77.8% (n=25) of these had a reference to their AE definition. Preventability was assessed in 19 studies (59.4%) (table 2).

AE descriptions

The total number of identified AEs was 8577 (range 0–34 per patient) in 33 samples, 3459 (range 0–27 per patient) in the general care population (13 GTT/ TT and 9 HMPS samples) and 5118 (range 0–34 per patient) in the intensive care population (11 samples). Preventability was reported in 16 samples (48.5%) with a total of 3785 identified preventable AEs (online supplemental material 1, table S6).

The most common types of AEs in general care (n=9 studies) were nosocomial infections (range, 6.8%-59.6%), medication-related (2.3%-48.6%) and surgical-related (0.9%-30.5%). Pulmonary-related (10.5%-36.7%), nosocomial infections (6.6%-40%) and medical technical product-related (1.3%-30.8%) were the most common types of AEs in intensive care (n=8 studies) (table 3).

Twenty-one studies assessed and described the severity of paediatric AEs. A majority of these (71.4%, n=15) used a modified version of the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Scale (online supplemental material 1, table S6). The studies assessing severity by the modified NCC MERP Scale, irrespective of population, had a range for minor consequences, category E, between 16.5% and 88.4% (mean, 56.9%); major, category F, 0.0% and 62.7% (28.9%); permanent, category G, 0.0% and 14.8% (4.0%); life-threatening, category H, 0.0% and 28.9% (7.4%) and death, category I, 0.0% and 15.7% (2.7%). The intensive care population had a mean of 11.7% for the two most severe categories-life-threatening and death, whereas the general care population had a mean of 3.1%.

Meta-analyses

The forest plot in figure 1 shows the primary outcome, that is, percentage of admissions with ≥ 1 AEs for 32 out of 33 samples. The range of percentage of admissions ≥ 1 AEs for GTT/TT was 6.1%-38.0% and 16.2%-83.9% for general and intensive care and the equivalent for HMPS was 0.0%-19.0%. The pooled estimates for the GTT/TT (general and intensive care populations) were 17.7% (95% PI 3.8%-53.8%) and 47.3% (95% PI 6.9%-91.6%), respectively, and 3.9% (95% PI 0.3%-33.7%) for the HMPS (general care). There was a statistically significant difference in the pooled estimates between the two populations within the GTT/TT methodology (p=0.0003).

First author, publication year,		Paediatric inpatients	Inclusion period, year		Academic level of	Inclusion and exclusion criteria of			Age, (years)	LOS, (days)
country Hospitals	Hospitals	admissions, n	(months)	Type of hospital(s)	hospital(s)	patients	Type of included units	Patient days, n	mean	mean
eneral care population, الالالة المالية 2014 من المالية	II metnodology	COOC	1000 2011 1461	Mittad	A discond		فالقنيما ممغ منتقالمتها	U.	VIC	VIC
Chapman 2014 - 06K	MULTICENTE	3992	7008—2011 (4p)	MIXed	IVIIXed	LUS > 24 nours	iviixed—not explicitly stated	CN	SN	SN
Davenport 2017 ⁴¹ ARG	Single centre	200	2013 (12)	Paediatric	NS	LOS ≥48 hours, if >1 hospitalisation the most recent one was included, no psychiatric patients and not for social reasons	ICU, neonatology, general care (multipurpose unit)	1690	4.4	8.5
Fajreldines 2019 ⁴⁵ ARG	Single centre	318	2015–2016 (13)	Tertiary care	Academic	LOS ≥48 hours, patient s<18 years	Neonatal care, PICU, nursery, paediatric	2257	3.0	NS
Kirkendall 2012 ⁵⁰ USA	Single centre	240	2009 (12)	Paediatric	Academic	LOS ≥24 hours, any age, no psychiatric and rehabilitation patients	Mixed—not explicitly stated	1206	7.8	5.1
Matlow 2012 ^{54–56} CAN	Multicentre*	3552	2008–2009 (12)	Mixed*	Mixed*	LOS ≥24 hours, patients <19 years, no obstetrics, or psychiatric patients and external transfers (except newborns)	Surgical, internal medicine, emergency, maternal/obstetrics, other	14738†	4.1†*	4.5†*
Paredes Esteban 2015, ⁵⁸ ESP	Single centre	95	2014 (12)	NS	NS	Patients admitted to paediatric surgery, no patients with adverse events as the reason for admission	Surgical	406	6.7	4.2
Salimath 2020 ^{46 60} IND	Single centre	520	NS (26‡)	Acute care	Academic	LOS≥24 hours, patients≤18 years, no psychiatric and rehabilitation patients	NICU, PICU, medicine, surgical, emergency and trauma†	2743†	NS	NS
Shah 2009 ⁵¹⁶¹ USA	Single centre	50	NS	Paediatric	Academic	Patients admitted to the otolaryngology service	Otolaryngology	87	NS	NS
Solevag, 2014 ⁶³ NOR	Single centre	494‡	2011 (3)	Acute care	Academic	Patients <18 years	Orthopaedic, surgical, ear/nose/ throat, medicine	2001†	6.8†	4.1†
Stockwell 2015 ⁶⁶ USA	Multicentre	600	2012 (1)	Paediatric	Academic	LOS between 24 hours and 6 months, patients <22 years, no rehabilitation, normal newborn nursery, day treatment, psychiatric or obstetric patients	NS	4372	6.2	7.3
Stockwell 2018 ^{13 67} USA	Multicentre	3790	2007–2012 (72)	Mixed	Mixed	LOS ≥24 hours, patients age <18 years, no psychiatric (without a concurrent acute medical issue) or rehabilitation patients	Mixed—not explicitly stated	21 789	SN	3.0§
Stroupe 2018 ⁶⁸ USA	Single centre	100	2014 (12)	Paediatric	Academic	Admitted patients ≤18 years	General paediatric, surgery, PICU, other	411	6.7	3.8
Unbeck 2014 ¹⁴ SWE	Single centre	600	2010 (12)	Acute care	Academic	LOS ≥24 hours, patient <19 years	Neonatal, surgical/orthopaedic, medicine, emergency medicine	5559	4.3	9.3
General care population, HMPS methodology	S methodology									
Brennan 1991 ^{11 43 47 48 52} USA	Multicentre¶	6661**	1984 (12)	Acute care	Mixed¶	Admitted patients, no psychiatric patients	All types¶	NS	NS	NS
Davis 2002 ^{42–44} NZL	Multicentre¶	1349†**	1998 (12)	Acute care	Mixed¶	Admitted patients, no day, psychiatric and rehabilitation-only patients	Mixed—not explicitly stated¶	4134‡	3.1†	3.1†
Letaief 2010 ⁵³ TUN	Single centre	116‡**	2005 (12)	Public	Academic	Admitted patients	Mixed—not explicitly stated	NS	NS	NS
Requena 2011 ⁵⁹ ESP	Multicentre	665	NS (NS)	NS	Mixed	LOS >24 hours, had a clinical history in the selected hospitals	NS	3318	NS	NS
Sommella 2014 ⁶⁴ ITA	Single centre	11‡**	2008 (12)	Acute care	NS	LOS > 24 hours, no day hospital discharges	Medical, surgical, ICU¶	NS	NS	NS

BMJ Qual Saf: first published as 10.1136/bmjqs-2022-015298 on 26 December 2022. Downloaded from http://qualitysafety.bmj.com/ on January 9, 2023 at Universitaetsbibliothek Bern. Protected by copyright.

Production Product	Table 1 Continued										
Support Difference State State Model	First author, publication year, country	Hospitals	Paediatric inpatients admissions, n	Inclusion period, year (months)	Type of hospital(s)	Academic level of hospital(s)	Inclusion and exclusion criteria of patients	Type of included units	Patient days, n	Age, (years) mean	Age, (years) LOS, (days) mean mean
Weed 35 Multerener, Moleculer, Molecu	Soop 2009 ⁶⁵ SWE	Multicentre ¶	159**	2003–2004 (12)	Acute care	Mixed¶	Admitted patients, no psychiatric, palliative care, rehabilitation, and day- only patients	Mixed—not explicitly stated¶	NS	NS	NS
Woods 3000 ⁴⁰⁰⁰⁰ Us, Multicenterity 319 ⁺⁺	Wilson 1995 ¹² AUS	Multicentre	2020**	1992 (12)	Acute care	Mixed¶	Admitted patients, no psychiatric and day-only patients	Different kind of medical and surgical†	8697†	4.1†	4.3†
Gages, 2009 ¹¹⁰ MLD Muterenerly 301 ¹¹ 2004 (12) Ander carle Model ⁻ explicition, Mod	Woods 2005 ^{69 70 74} USA	Multicentre	3719**	1992 (12)	Profit/non-profit, government	Mixed¶	Admitted patients, no psychiatric, rehabilitation and drug/alcohol treatment patients	Mixed—not explicitly stated	NS	N	NS
Interview care population. GTTTT methodology1 Agraval 2010 ⁴ VISA Multicarre 734 2005 (J) Mied 5301	Zegers, 2009 ^{33 75} NLD	Multicentre¶	330**	2004 (12)	Acute care	Mixed¶	LOS of >24 hours, no psychiatric, obstetrics and <1 year patients	Mixed—explicitly stated¶	NS	NS	NS
Agareued 2010 ¹⁶ UGAMitterine7342005 (a)MiedMiedDisc.selfbrours no postprearble cardie:PICU20116.3Henper 2010 ¹⁶ MGSSingle certre932011 (a)PadiettiNC05-34 hoursNCU64637NGHenper 2010 ¹⁶ MLSSingle certre932011 (a)PadiettiNCNCU64637NGHenper 2010 ¹⁶ MLSSingle certre932011 (a)PadiettiNCNCU64637NGHenper 2010 ¹⁶ MLSSingle certre932013 (a)PadiettiNCAdmited palentisPCU5643464Janes 2007 ¹⁶ MLSSingle certre2392003 (a)PadiettiNCAdmited palentisPCU5643Admited palentis464Janes 2007 ¹⁶ MLSMilformet1172008-2003 (13)PediettiMeedMCPCU5643NCMater 2006 ¹⁶ MLSMultormet792017-2018 (NS)MeedNCMeed055400 NSNC701Mater 2006 ¹⁶ MLSMultormet792004-2005 (S)MeedNCNCNC701704704Mater 2006 ¹⁶ MLSMultormet792004-2005 (S)MeedNC1055400 NSNCNC706706Mater 2005 ¹⁶ MLSMultormet2012004-2005 (S)MeedNC1055400 NSNC700717 (G)706Vertue 2012 ¹⁷ MLSMultormet2006 (G)NSNSNS <td>Intensive care population, GT</td> <td>T/TT methodology^{††}</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Intensive care population, GT	T/TT methodology ^{††}									
Barrinouroue 2010 ⁶ AGI Stople centre 84 2006 (12) Paddintic Incl Incl 6451 NL Hooper 2014 ⁴ MLS Single centre 39 2011 (3) Paddintic Admitted patients PCU 164 NL Jono-Baron 2014 ⁴ MLS Single centre 39 2011 (3) Paddintic NL Admitted patients PCU 1542 Admitted patients PCU 1542 NL Jarsen 2004 ⁴ USA Single centre 29 2012-2018 (1) Paddintic NL Admitted patients PCU 1542 Admitted patients PCU <td< td=""><td>Agarwal 2010³⁸ USA</td><td>Multicentre</td><td>734</td><td>2005 (4)</td><td>Mixed</td><td>Mixed</td><td>LOS ≥48 hours, no postoperative cardiac patients</td><td>PICU</td><td>5201</td><td>6.3</td><td>7.1</td></td<>	Agarwal 2010 ³⁸ USA	Multicentre	734	2005 (4)	Mixed	Mixed	LOS ≥48 hours, no postoperative cardiac patients	PICU	5201	6.3	7.1
Hooper 2014 ⁴ /M.S. Single centre 59 2011 (3) Packativic Admitted patients. P(U) 164 N15 <i>Doro-Baron.</i> 201 ⁴ /M.G. Multicentre 145 2018-2019 (11) Pulcic N5 US 2014 (N) Packativic 1543 15 451 <i>Doro-Baron.</i> 201 ⁴ /M.G. Single centre 117 208-2009 (12) Packativic Minited Patients. P(U) 921 N5 Matted patients. 117 208-2009 (12) Mined* Nined* Nine 921 921 921 Nine Matted patients. Null feature 19 2001-2005 (12) Mined* Nine Nine 921 011 17341 921 1734 Matted patients. Null feature 19 2001-2005 (12) Nined* Nine Nine Nine Nine 163 17341 1734 17341 1736 163 173 164 163 163 163 163 163 163 163 163 163 163	Barrionuevo 2010 ³⁹ ARG	Single centre	484	2006 (12)	Public	NS	LOS > 24 hours	NICU	6465†	NS	13.4†
Increasion Indicating Idda	Hooper 2014 ⁴⁸ AUS	Single centre	59	2011 (3)	Paediatric	Academic	Admitted patients	PICU	164	NS	2.8
Jasen 2017Single centre2592002-2003 (12)RediatioAdmitted patientsP(U92.10.01Matlow 2017Matlow 2017Matlow 2017Matlow 2013Matlow 2013Mat	Jorro-Baron 2021 ⁴⁹ ARG	Multicentre	1465	2018–2019 (11)	Public	NS	LOS >24 hours, patients <18 years and admitted for acute care	PICU	15 842	4.6†	10.8†
Mattore 2013 ⁻⁶⁴⁵ C.M. Multicentre 11 2008-2009 (12) Mixed ⁺ LOS 224 hours, patients <19 easis independences of externation of externation services (except newborns). NUL, PICU T341 0.01 Maziero 2020 ⁹ BRA Multicentre 79 2017-2018 (NS) Public NS Admited patients <19 easis independences of psychiatic patients and externation (respect newborns).	Larsen 2007 ⁸ USA	Single centre	259	2002-2003 (12)	Paediatric	Academic	Admitted patients	PICU	962†	NS	1.6§
Maziero 2020 ⁶ BRAMultientre792017–2018 (NS)PublicNSAdmitted patientsNICU, PICUNSNSSharek 2006 ⁶ USA/CANMultientre7492004–2005 (3)Mixed(05 ≥48 hours)NICU17106NSVertura 2012 ⁷ BRASingle centre2182006 (6)NSNS(05 ≥2 hours)NICU2958NSVertura 2012 ⁷ DRASingle centre2182006–2012 (72)NSNS(05 ≥2 hours)NICU2958NSVertura 2012 ⁷ DRASingle centre2182006–2012 (72)NSNS(05 ≥2 hours)Patient-18 years, noPCU2958NSVertura 2013 ⁷ DRASingle centre80142006–2012 (72)NSNS(05 ≥2 hours)PRIENTPCU512NSVertura 2013 ⁷ DRASingle centre80142006–2012 (72)NSNS(05 ≥2 hours)PRIENTPCU512NSVertura 2013 ⁷ DRASingle centre80142012 (4)PediatricAcademic(05 ≤48 hours)PCU707071Verture 1010 ¹¹ Single centre80142012 (4)PediatricAcademic(05 ≤48 hours)PCU512NSVerture 1010 ¹¹ Single centre80142012 (4)PediatricAcademic(05 ≤48 hours)PCU512NSVerture 1010 ¹¹ Single centre80142012 (4)PediatricAcademic(05 ≤48 hours)PCU512NSVerture 1011Sin	Matlow 2012 ^{54–56} CAN	Multicentre*	117	2008–2009 (12)	Mixed*	Mixed*	LOS ≥24 hours, patients <19 years, no obstetrics or psychiatric patients and external transfers (except newborns)	NICU, PICU	1574†	0.0†	13.5†
Sharek 2006 ⁶⁰ USA/CANMulticentre7492004–2005 (3)MixedIOS ≥48 hoursINCU17 106NSVerhaa, 2012 ¹¹ BRASingle centre2182009 (6)NSNSIOS ≥48 hoursNCU2958NSVerhaa, 2012 ¹¹ BRASingle centre2182006–2012 (72)NSNSIOS ≥2 hours, patient <18 years, no.	Maziero 2020 ⁵⁷ BRA	Multicentre	79	2017-2018 (NS)	Public	NS	Admitted patients	NICU, PICU	NS	NS	NS
Ventura 2012 ¹ BRASingle centre2182009 (6)NSNSIOS \geq 48 hoursNCU2358NSVerlaat, 2018 ¹⁷ NLDMulticentre482006–2012 (72)NSNSIOS \geq 2 hours, patient <18 years, no	Sharek 2006 ⁶² USA/CAN	Multicentre	749	2004-2005 (3)	Mixed	Mixed	LOS ≥48 hours	NICU	17 106	NS	22.8
Verlaat, 2018 ⁷³ NLD Multicentre 48 2006–2012 (72) NS NS IOS 22 hours, patient < 18 years, no PCU 6081 6.4 Vermeulen 2014 ¹³ ZAF Single centre 80 ± ± 2012 (4) Paediatric Academic LOS >48 hours, patients included only PCU 6.081 6.4 Vermeulen 2014 ¹³ ZAF Single centre 80 ± ± 2012 (4) Paediatric Academic LOS >48 hours, patients included only PCU 512 NS Vorticome for the total cohort. Once if > 1 admission once if > 1 admission PCU 512 NS Total cohort. Verticome for the total cohort. PCU 512 NS Total cohort. Unce if > 1 admission PCU 512 NS Academic. Unce if > 1 admission PCU 512 NS Academic. Academic. IOS >48 hours, patients included only PCU 512 NS Academic. Sa Sa Sa Sa Sa	Ventura 2012 ⁷¹ BRA	Single centre	218	2009 (6)	NS	NS	LOS ≥48 hours	NICU	2958	NS	13.5
Vermeulen 2014 ⁷³ ZrF Single centre 80## 2012 (4) Paediatric Academic LOS >48 hours, patients included only PICU 512 NS *Outcome far the total cond. *Outcome far the total cond. •Outcome far total cond.	Verlaat, 2018 ⁷² NLD	Multicentre	48	2006–2012 (72)	NS	NS	LOS ≥2 hours, patient <18 years, no patients with corrected age <36 weeks (GA)	PICU	608†	6.4	12.7†
 Outcome for the total cohort. Additional data from authors. Additional data from authors. Calculations are made. Silvedian. Finediation for the total cohort. Additional data from authors. 	Vermeulen 2014 ⁷³ ZAF	Single centre	80##	2012 (4)	Paediatric	Academic	LOS >48 hours, patients included only once if >1 admission	PICU	512	NS	4.0§
	 Outcome for the total cohort. †Additional data from authors. †Calculations are made. Silvedian. Silvedian. Sinter total cohort in a st. **Paediaric cohort. TS studies using the HMPS methodology #Ranospective cohort. Academic, academic medical centre/unit. Care unit, T, finger Tool. 	tudy with both pædiatric ar y did not predominantly inc versity hospital; Adm, admi	nd adult patients, inform: clude intensive care patie ssion; GA, gestational ag	ation for the paediatric cohort not ints. e: GTT, Global Trigger Tool; HMPS,	reported. Harvard Medical Practice Stur	dy, iCU, intensive care unit, L(DS, length of stay; Mixed, both paediatric and adu	ut hospital type; NICU, neonatal inters	sive care unit; NS, not .	specified; PICU, pa	ediatric intensive

	· · ·								
First author, publication year	RRR method	Method of record selection	Method of review*	> 1 AE/ patient	Commission/ omission	Data on IRR outcome	Time frame of AE detection, in addition to index admission	AE definition†	Preventability reporting
General care population, GTT/TT methodology	tion, GTT/TT me	thodology							
Chapman, 2014 ⁴⁰	IT	Random	2-stage; (1) 40 triggers, trained reviewer; (2) trained physician	Yes	Both	No	Before; after	Wider than IHI	No
Davenport, 2017 ⁴¹	GП	Random	2-stage; (1) 52 triggers, trained physicians; (2) trained physicians	Yes	NS	Yes	Before NS; after	IHI like	No
Fajreldines, 2019 ⁴⁵	TT	Random	NS	Yes	NS	No	NS	NS	No
Kirkendall, 2012 ⁵⁰	GП	Random	2-stage; 1) 53 triggers, trained nurses; (2) physician	Yes	Commission only	Yes	Before; after	IHI like	No
Matlow, 2012 ^{54–56} ‡	E	Random	2-stage; (1) 35 triggers, trained nurses, health record technologists/medical record technicians; (2) trained physicians	Yes	Both	Yes	Before; after	HMPS like	Yes
Paredes Esteban, 2015 ⁵⁸	GП	Unclear	2-stage; (1) NS, trained nurses; (2) trained physicians	Yes	NS	No	Only index	HMPS like	No
Salimath, 2020 ^{46 60}	II	Random	2-stage; (1) 40 triggers, trained pharmacists; (2) trained physicians	Yes	NS	No	Before NS; after	Other	No
Shah, 2009 ⁵¹⁶¹	II	Random	2-stage; (1) 43 triggers, physicians; (2) physicians	Yes	Both	Yes	Before; after NS	Wider than IHI	No
Solevag, 2014 ⁶³	ΤΤ	Convenience	Unclear; 39 triggers, trained physician	Yes	NS	No	Before; after	Wider than IHI	No
Stockwell, 2015 ⁶⁶	Ħ	Random	2-stage; (1) 51 triggers, trained nurses, pharmacists; (2) trained physicians	Yes	Both	No	Before NS; after	IHI like	Yes
Stockwell, 2018 ^{13 67}	Ц	Random	2-stage; (1) 27 triggers, trained nurses; (2) trained physicians	Yes	NS	Yes	Before; after	IHI like	Yes
Stroupe, 2018 ⁶⁸	Ш	Random	2-stage; (1) 54 triggers, trained nurses; (2) trained physicians	Yes	Both	Yes	Before NS; after	Wider than IHI	Yes
Unbeck, 2014 ¹⁴	TT	Random	2-stage; (1) 88 triggers, trained nurses; (2) trained physicians	Yes	Both	Yes	Before; after	Wider than IHI	Yes
General care population, HMPS methodology	tion, HMPS met	hodology							
Brennan, 1991 ^{1147 52} HMPS	² HMPS	Random	2-stage; (1) 18 criteria, trained nurses, medical record analyst; (2) trained physicians	No§	Both	Yes	Before; after	HMPS like	No
Davis, 2002 ^{42–44}	HMPS	Random	2-stage; (1) 18 criteria, trained nurses; (2) trained medical officers	No§	Both	Yes	Before; after	HMPS like	Yes

Table 2 Continued									
First author, publication year	RRR method	Method of record selection	Method of review*	> 1 AE/ patient	Commission/ omission	Data on IRR outcome	Time frame of AE detection, in addition to index admission	AE definition†	Preventability reporting
Letaief, 2010 ⁵³	HMPS	Random	2-stage; (1) 18 criteria, trained medical student; (2) physicians	No§	Both	Yes	Before; after	Wider than IHI	Yes
Requena, 2011 ⁵⁹	HMPS	Random/total sample¶	2-stage; (1) 19 criteria, NS; (2) NS	Yes	NS	No	NS	Wider than IHI	Yes
Sommella, 2014 ⁶⁴	HMPS	Random	2-stage; (1) 16 criteria, trained physicians; (2) trained physicians	No	NS	No	Before NS; after	HMPS like	No
Soop, 2009 ⁶⁵	HMPS	Random	3-stage; (1) 18 criteria, trained nurses; (2) trained physicians; (3) member of the Scientific Council	No§	Both	Yes	Before; after	HMPS like	Yes
Wilson, 1995 ¹²	HMPS	Random	2-stage; (1) 18 criteria, trained nurses; (2) trained medical officers	No§	Both	Yes	Before; after	HMPS like	Yes
Woods, 2005 ^{69 70 74}	HMPS	Random	2-stage; (1) 18 criteria, trained nurses; (2) trained physicians	No	Both	Yes	Before; after	HMPS like	Yes
Zegers, 2009 ^{33 75}	HMPS	Random	3-stage; (1) 18 criteria, trained nurses; (2–3) trained physicians	Yes	Both	Yes	Before; after	HMPS like	Yes
Intensive care population, GTT/TT methodology**	lation, GTT/TT m	lethodology**							
Agarwal, 2010 ³⁸	Ш	Random	2-stage; (1) 22 triggers, trained nurses, physicians; (2) trained physician, pharmacist	Yes	Both	No	Before; after	Wider than IHI	Yes
Barrionuevo, 2010 ³⁹	TT .	Total sample	2-stage; (1) 19 triggers, trained nurses; (2) trained physician	Yes	NS	No	NS	Wider than IHI	Yes
Hooper, 2014 ⁴⁸	TT	Random	Unclear; 22 triggers, trained investigators	Yes	Commission only	Yes	Before; after	Wider than IHI	No
Jorro-Baron, 2021 ⁴⁹	Ħ	Random	2-stage; (1) 37 triggers, trained PICU staff; (2) trained physicians	Yes	Both	No	NS	NS	Yes
Larsen, 2007 ⁸	TT	Every seventh admission	Unclear; 46 triggers, nurses, physicians	Yes	NS	Yes	NS	NS	Yes
Maziero, 2020 ⁵⁷	TT	NS	2-stage; (1) NS, reviewer; (2) physician	Yes	NS	No	NS	NS	No
Sharek, 2006 ⁶²	TT	Random	2-stage; (1) 17 triggers, trained nurses; (2) trained physician	Yes	Both	No	NS	Wider than IHI	Yes
Ventura, 2012 ⁷¹	TT	Total sample	Unclear; 14 triggers, researcher	Yes	NS	No	NS	Wider than IHI	Yes
Verlaat, 2018 ⁷²	TT	Random	2-stage; (1) 19 triggers, trained physician; 2) trained physician	Yes	NS	Yes	Before; after	HMPS like	Yes
									Continued

BMJ Qual Saf: first published as 10.1136/bmjqs-2022-015298 on 26 December 2022. Downloaded from http://qualitysafety.bmj.com/ on January 9, 2023 at Universitaetsbibliothek Bern. Protected by copyright.

Table 2 Continued									
First author, publication year	Method of record RRR method selection	Method of record selection	Method of review*	> 1 AE/ patient	Commission/ omission	Data on IRR outcome	Time frame of AE detection, in addition to index admission	Preventab AE definition† reporting	Preventability reporting
Vermeulen, 2014 ⁷³	Ш	Random	2-stage; (1) 23 triggers, trained medical student; (2) medical director	Yes	Both	No	Before NS; after	Wider than IHI	No
IHI does not require any additional monitoring, treatment or hospitalisation. *Number of review stage(s); number of triggers/screening criteria, record review to HMPS like requires temporary or permanent disability, death or prolonged hospit additional monitoring, treatment, or hospitalization. #Outcome for the total cohort, including both general and intensive care populati §Additional data from authors. ¶This study merged paediatric data from three studies which used different sampl **No study using the HMPS methodology included mainly intensive care patients. AE, adverse event; GTT, Global Trigger Tool; HMPS, Harvard Medical Practice Study Trigger Tool.	additional monit e(s); number of ti porary or permar eatment, or hosp cohort, including uthors. uthors. altatric data from MPS methodology 5lobal Trigger Toc	oring, treatment riggers/screening nent disability, de bitalization. both general and three studies whi / included mainly J; HMPS, Harvard	 IHI does not require any additional monitoring, treatment or hospitalisation. *Number of review stage(s), number of triggers/screening criteria, record review training, type of reviewer(s)/review stage. THMPS like requires temporary or permanent disability, death or prolonged hospitalisation; IHI like requires additional monitoring, treatment or hospitalisation. Totome for the total cohort, including both general and intensive care population. Outcome for the total cohort, including both general and intensive care population. Additional data from authors. This study merged paediatic data from three studies which used different sampling techniques. **No study using the HMPS methodology included mainly intensive care patients. At advectore event; GTT, Global Trigger Tool; HMPS, Harvard Medical Practice Study methodology; IHI, Institute for Healthcare Improvement; IRR, interrater reliability; NS, not specified; RRR, retrospective record review; TT, Trigger Tool. 	f reviewer(s)/rev ike requires addi	iew stage. Itional monitoring, treatm r Healthcare Improvement	ent or hospitalisatio ; IRR, interrater relia	n, or that results in death; V sbility; NS, not specified; RRI	<i>i</i> ider than IHI does 3, retrospective rec	not require any ord review; TT,

Online supplemental material 1, figures S2–S5 present forest plots for the secondary outcomes. In 24 samples (GTT/TT), AEs per 100 admissions (general care, range 6.8–93.8; intensive care, 30.2–325.0) were supplied or could be calculated. The pooled estimate for the general care population was 24.8 AEs per 100 admissions (95% PI 4.2–145.2) and 103.6 AEs per 100 admissions (95% PI 5.3–699.7) for intensive care (table 4; online supplemental material 1, figure S2). An overview of the pooled estimates and related measures for the primary and secondary outcomes is shown in table 4.

In 22 samples (GTT/TT), AEs per 1000 patient days varied between 15.5 and 390.8 for general care and 22.6 and 599.1 for intensive care. The pooled estimates for AEs per 1000 patient days were 48.3 (95% PI 5.9–393.1) and 126.2 (95% PI 6.4–2495.1) for general care and intensive care, respectively. Half of the studies for intensive care had over 100 AEs per 1000 patient days (range 195.7–599.1) (table 4; online supplemental material, figure S3).

Of the 16 samples that reported preventability, the pooled percentage of preventable AEs for GTT/TT (general and intensive care populations) was 58.6% (95% PI 7.4%–96.2%) and 67.4% (95% PI 4.5%–98.9%). The corresponding for the HMPS was 53.2% (95% PI 10.4%–91.8%) (table 4; online supplemental material, figure S4). The pooled percentage of admissions with preventable AEs (12 samples) was for the GTT/TT (general and intensive care) 7.3% (95% PI 0.0%–100.0%) and 25.0% (95% PI 2.5%–81.3%) and for HMPS 2.3% (95% PI 0.0%–59.3%) (table 4; online supplemental material, figure S5).

Quality assessment and sensitivity analysis

Several methodological concerns were identified during the quality assessment process.

Concerning overall assessments, risk of bias was assessed as *high* in 85% compared with 44% in the 9 GTT/TT and 13 HMPS studies for the general population and 100% for the intensive care population (n=10, GTT/TT). When compared with GTT/TT studies, HMPS studies more frequently had both a *low* risk of bias with *low* applicability concerns at the domain level (online supplemental material 1, table S7, figures S6-S7).

The stratified analysis exploring heterogeneity was based on the quality assessment and percentage of admissions with ≥ 1 AE as the outcome. Lower AE outcomes were detected where the risk of bias was rated as *high* or *unclear* in the domain 'record review process' than in those with a *low* risk of bias for general care (GTT/TT) (online supplemental material 1, figure S8). For the HMPS methodology, variation is driven by the unclear category, which hampers interpretation (online supplemental material 1, figure S9). For the intensive care population, studies with *high* risk of bias detected lower levels of AEs in the domain 'patient

Study reference number(s) →	Genera	General care population	pulation							Intensive ca	Intensive care population	u					
	GTT/TT	GTT/TT methodology	ology					HMPS r	HMPS methodology	y GTT/TT methodology	hodology						
types of AEs	40	41	45*	54-56	8	99	13 67	29	69 70 74	88	39	48	57	62	11	72	73
Nosocomial infection [†]	9.2	59.6	42.8	I	I	18.6	6.8	13.8	I	6.6	19.2	9.2	40.0	27.8	13.5	20.0	7.3
Pulmonary‡	3.6	1.9	I	I	4.7	12.8	16.8	I	I	19.2	13.7	36.7	16.7	11.0	10.5	17.8	23.2
Skin, tissue or blood vessel harm§	8.1	1.9	I	I	32.6	I	23.8	I	I	8.0	I	I	33.3	15.9	6.0	4.4	12.3
Medication related	2.5	3.8	48.6	12.5	2.3	I	I	37.9	19.1	I	I	1.0	3.3	I	I	I	I
Medical technical product (eg, catheter or tube)**	I	I	I	I	4.7	14.5	I	I	I	15.1	30.8	5.1	о. С.	1.3	6.0	4.4	20.7
Gastrointestinal††	4.5	I	I	I	37.2	11.8	8.3	I	I	5.6	I	5.1	I	5.2	1.0	11.1	4.6
Neurological‡‡	1.0	I	I	I	I	5.3	3.3	I	I	4.7	10.3	2.0	I	16.0	31.1	13.3	5.1
Renal, endocrine, fluid and electrolytes§§	5.6	I	I	0.8	2.3	6.3	5.9	I	I	6.8	I	14.3	I	5.4	21.1	4.4	17.4
Surgical 11	0.9	9.6	I	30.5	I	8.7	7.5	I	16.3	1.7	I	7.1	I	0.2	I	I	1.9
Cardiovascular***	I	I	I	I	I	5.4	4.6	I	I	14.4	1.4	8.2	I	8.7	4.1	4.4	1.2
Haematological+++	3.4	1.9	I	I	4.7	5.1	3.8	I	I	3.9	12.3	2.0	3.3	1.1	0.5	6.7	1.2
Pain###	I	I	I	I	11.6	I	5.8	I	I	9.8	I	I	I	I	I	I	1.9
Deterioration in vital signs§§§	7.5	1.9	I	I	I	I	I	I	I	I	I	2.0	I	I	I	11.1	I
Other	53.7	19.2	I	56.3	I	11.8	13.7	48.2	65.5	4.2	12.3	7.1	I	7.6	6.2	2.2	3.1
Other Minicipation 55.7 19.2 50.5 4.2 11.3 7.1 48.2 65.5 4.2 11.3 7.1 - Type not reported by the respective study. ************************************	23.7 ch type. espective pplied in th podstream I tube mal I tube mal tration, ex nedication g, agitatio g, agitatio els, acute r blood pre leeding frr r y arrest, c r y arrest, c	19.2 study. ne publicat infection, position re travasation stop, drug ng tube cc a, antiemet a, antiemet a, antiemet antedirium return to si ssure, arrh on feeding olled pain. ardiac or pi eaction bi	- tion. nosocomi squiring re aquiring re injury, ni j level out injury, ni tic given, c tic given, c tic given, c tic given, c tic given, c turgery, suu ythmia, c j tube, blo pulmonary inth-relatei	56.3 al infection, positioning, of range, hy: n, intravenou ervous syster lucose disorc gical complie irdiac depres od transfusic ' arrest, or ral	– pneumoni njury, pres aluronic ac delay in d ars, dehyc cation ns, deep v sion/comp pid respon ple redraw	11.8 a, sepsis, u orax, posti ssure sore, cid adverse complicat iagnosis o elirium/agi dration, flu dration, flu stration, can venmise, can ven throml	11.8 13.7 48.2 b5.2 epsis, urinary tract infection, wound as, postextubation tridor, triintubation adverse reaction, medication related, amplication, tube complication (foley, ynosis of gastric perforation, emesis/v ynosis of gastric perforation, emesis/v inum/gitation, neurological complica- tion, fluid overload, hyperglycaemia, mise, cardiac rhythm derangements (e n thrombosis, emboli, haemorrhage/h ream activation, resuscitation, vital s care-related, complication of procedi	48.2 t infection, strind down, skin medication onplication, thypergly hypergly m derange oli, haemoi susscitation of	11.8 13.7 48.2 65.5 sepsis, urinary tract infection, wound infection. as postextubation stridor, reintubation, resolira ra sore, skin breakdown, skin lesion, skin necro ladverse reaction, medication related. omplication, tube complication floby, chest dra gnosis of gastric perforation, emesis/vomiting, i irium/agitation, neurological complication, over ation, fluid overload, hyperglycaemia, hypoglyca mise, cardiac rhythm derangements (eg, brady in thrombosis, emboli, haemorrhage/haematom e team activation, resuscitation of procedure or tree , care-related, complication of procedure or tree	11.8 13.7 48.2 65.5 4.2 12.3 7.1 – 7.6 respis, urinary tract infection, wound infection. sepsis, urinary tract infection, wound infection. ax, postextubation stridor, reintubation, respiratory depression/compromise, unplanned extubation. are sore, skin breakdown, skin lesion, skin necrosis, skin problems. I adverse reaction, medication related. omplication, tube complication (foley, chest drain or nasogastric tube). gnosis of gastric perforation, emesis/vomiting, necrosis of digits. inium/agitation, neurological complication, oversedation, seizure, stroke, withdrawal symptoms. ation, fluid overload, hyperglycaemia, hypoglycaemia, renal dysfunction, urinary retention. imise, cardiac rhythm derangements (eg, bradycardia, tachycardia, other arrhythmias), hypotension. in thrombosis, emboli, haemorrhage/haematoma, postoperative bleeding, thrombocytopenia. care-related, complication, vital sign changes. care-related, complication, vital sign changes.	12.3 bion/compromi oblems. astric tube). ijgits. izure, stroke, v dysfunction, u dysfunction, u th diadnostic.	v.1 se, unplan vithdrawal urinary rete arrhythmia: thromboc	– ned extubé symptoms s), hypoten ytopenia.	/ .b stion. sion.		7:7	ñ

							Syste	matic revie
GTT/TT Studies	N of admissions	Sample size				% of a	dmissions	95% CI
	with ≥ 1 AE					w	rith ≥ 1 AE	
Population = General ca	are							
Shah, 2009	19	50	_				38.0	[25.9; 51.8]
Paredes Esteban, 2015	31	95	_	-			32.6	[24.0; 42.6]
Stroupe, 2018	14	100					14.0	[8.5; 22.1]
Davenport, 2017	43	200					21.5	[16.4; 27.7]
Kirkendall, 2012	62	240		-			25.8	[20.7; 31.7]
Fajreldines, 2019¥	26	318	-				8.2	[5.6; 11.7]
Solevåg, 2014	41	494	+				8.3	[6.2; 11.1]
Salimath, 2020	159	520	+	- -			30.6	[26.8; 34.7]
Unbeck, 2014	204	600		-			34.0	[30.3; 37.9]
Stockwell, 2015	146	600	-				24.3	[21.1; 27.9]
Matlow, 2012	218	3552	÷				6.1	[5.4; 7.0]
Stockwell, 2018	303	3790	Ħ				8.0	[7.2; 8.9]
Chapman, 2014	567	3992	Ŧ				14.2	[13.2; 15.3]
Random effects model		14551	\diamond				17.7	[12.5; 24.5]
Prediction interval								[3.8; 53.8]
Population = Intensive	care							
Verlaat, 2018	20	48	-	-	_		41.7	[28.8; 55.7]
Hooper, 2014	33	59					55.9	[43.3; 67.8]
Maziero, 2020	22	79						[19.2; 38.6]
Vermeulen, 2014	61	80			-			[65.9; 84.2]
Matlow, 2012	19	117						[10.6; 24.0]
Ventura, 2012	183	218						[78.5; 88.2]
Larsen, 2007	152	259						[52.6; 64.5]
Barrionuevo, 2010	82	484	-				16.9	[13.9; 20.5]
Agarwal, 2010	454	734					61.9	[58.3; 65.3]
Jorro-Baron, 2021	570	1465		+			38.9	[36.4; 41.4]
Random effects model		3543					47.3	[31.9; 63.2]
Prediction interval								[6.9; 91.6]
			0 20	40	60	80	100	
HMPS Studies	N of admissions with ≥ 1 AE	Sample size					dmissions ⁄ith ≥ 1 AE	95% Cl
Population = General c	are							
Sommella, 2014\$	0	11					0.0	[0.0; 25.9]
Letaief, 2010\$	22	116					19.0	[12.9; 27.0]
Soop, 2009¥	8	159					5.0	[2.6; 9.6]
Zegers, 2009	7	330	#				2.1	[1.0; 4.3]
Requena, 2011	24	665	÷				3.6	[2.4; 5.3]
Davis, 2002¢	102	1349	÷				7.6	[6.3; 9.1]
Wilson, 1995¢	218	2020					10.8	[9.5; 12.2]
Woods, 2005	39	3719	E.				1.0	[0.8; 1.4]
Brennan, 1991\$¥	86	6661	E .				1.3	[1.0; 1.6]
Random effects model Prediction interval		15030	۵				3.9	[2.0; 7.6] [0.3; 33.7]
				1	1	1		
			0 20	40	60	80	100	

Figure 1 Forest plot of percentage of admissions with \geq 1 adverse event (AE) for general care and intensive care populations and methodology, ordered by sample size. \$ Sum of subgroups. ¥ Calculation of number of admissions with AEs. ¢ Scored 2–6 on the causation scale compared with 4–6 for other studies using this scale to determine whether an AE was caused by healthcare management rather than the patient's disease. GTT, Global Trigger Tool; HMPS, Harvard Medical Practice Study; TT, Trigger Tool.

	General care population	opulation	General care population	lation	Intensive care population	population	
	HMPS methodology	ilogy	GTT/TT methodology	gy			P value between
	N of samples	Pooled estimates (95% PI)	N of samples	Pooled estimates (95% PI)	N of samples	Pooled estimates (95% PI)	populations (GTT/TT)
Primary outcome							
Percentage of admissions with ≥1 AEs	6	3.9 (0.3–33.7)	13	17.7 (3.8–53.8)	10	47.3 (6.9–91.6)	0.0003
Secondary outcomes							
AEs per 100 admissions	I	1	13	24.8 (4.2–145.2)	11	103.6 (15.3–699.7)	< 0.0001
AEs per 1000 patient days	I	I	12	48.3 (5.9–393.1)	10	126.2 (6.4–2495.1)	0.0418
Percentage of preventable AEs 5	5	53.2 (10.4–91.8)	4	58.6 (7.4–96.2)	7	67.4 (4.5–98.9)	0.5355
Percentage of admissions with preventable AEs	4	2.3 (0.0–59.3)	m	7.3 (0.0–100.0)	L)	25.0 (2.5–81.3)	0.0467

selection' than those rated as *low* risk of bias (online supplemental material 1, figure S10). In all three strata, *high* risk of bias for the domain 'outcomes' was typically associated with higher AE rates compared with *low* risk of bias. Nevertheless, the limited sample size does not provide enough evidence to draw any solid conclusions.

DISCUSSION

We conducted a systematic review and a meta-analysis, consisting of 32 studies with 44 publications examining the incidence and characteristics of AEs detected using three commonly used record review methods (GTT, TT and HMPS). Nosocomial infections were common in both populations and most of the AEs were less severe. There was substantial between-study heterogeneity and overall high risk of bias in most studies. The PIs for the primary outcome for GTT/TT studies were 3.8%-53.8% and 6.9%-91.6% (general care and intensive care populations) and 0.3%-33.7% for the HMPS studies (general care). The PIs for the percentage of preventable AEs for GTT/TT studies were 7.4%-96.2% and 4.5%-98.9% (general care and intensive care) and the equivalent for HMPS studies was 10.4%-91.8%.

Incidence and characteristics of adverse events in paediatric inpatient care

Our review confirms substantial heterogeneity between general care and intensive care studies, as well as between methodologies (GTT/TT and HMPS). However, the results also display a high level of heterogeneity within populations. The degree of heterogeneity is in accordance with previously published systematic reviews.²² ²³ ²⁵ ⁷⁶ The majority of studies were judged to be at high risk of bias, which also lowers the trust we place in the summary estimates. Therefore, caution is needed when drawing conclusions from the pooled data of the combined studies. We urge the reader to focus on the given PIs when interpreting the pooled data.

Berchialla et al^{25} focused solely on paediatric inpatient AEs in their systematic review and reported a pooled incidence of AEs at 2.0%. This is lower than the pooled incidence of admissions with ≥ 1 AE using the GTT/TT methodology, shown in the present review: 17.7% for the general care population and 47.3% for the intensive care population. However, it is in line with the 3.9% for studies conducted using HMPS methodology. Their inclusion of studies using only the HMPS's AE definition may partly explain the difference, as the threshold for inclusion of an AE is higher due to the requirement of temporary or permanent disability, death or increased length stay. This could have led to minor, but perhaps commonly occurring AEs, being excluded with the risk of underestimation of AEs as a consequence.

Sauro *et al*²³ included, in addition to record review, other data collection methods, and found a pooled estimate of 1.4 AEs per 100 paediatric admissions and up to 11.9 AEs per 100 admissions in adult care. This is also considerably lower than our corresponding estimate for GTT/TT studies at 24.8 and 103.6 (general care and intensive care populations) AEs per 100 admissions. On the other hand, a newly published systematic review²⁹ including GTT/TT studies in general care reported a pooled incidence of 30.0 AEs per 100 adult admissions which is higher compared with our findings in the general care population.

Half of the studies assessed and reported preventability, both for general and intensive care, and around 60% of AEs were identified as preventable. However, as discussed by Hibbert *et al*,⁶ the assessment of preventability is a subjective judgement and comparison between studies is to be done with caution. This, therefore, is a methodological limitation. Panagioti et al^{22} included both adult and paediatric populations and showed an overall pooled prevalence of 6% for preventable AEs. This is in line with our preventability estimates in GTT/TT studies of 7.3% for admissions in general care but is higher compared with the 2.3% found in the HMPS studies. However, we found a pooled estimate of 25% for preventable AEs for intensive care compared with 18% in the study by Panagioti et al.²²

A longitudinal retrospective record review study indicated an increased frequency of AEs over time, where one explanation was the increased number of patients with less complex conditions receiving day and outpatient care instead of inpatient care. This leads to an increased proportion of seriously ill patients in hospitals, and this may affect the AE rates for inpatient care.⁷⁷

Important aspects of the variation in AE rates are the context and case mix of patients such as inclusion of units, medical specialities, hospital types, academic level of the hospital, patient age and comorbidity, and level of care. In both general care and intensive care populations, nosocomial infection was among the most common type of adverse event, also identified as one of the main causes of morbidity and mortality for paediatric inpatients.⁷⁸ Paediatric patients have many risk factors for infections related to, among other things, immunodeficiencies and poor skin barrier. Skin harm is a predisposing factor for nosocomial infections,⁷⁹ and was the overall third most common type of AEs in the current review. It is important to keep in mind the considerable variation regarding the taxonomy of reported types of AE used, which makes comparisons between studies difficult.

Study methodology

The use of record review methodology for specific populations seems to have increased over the last few decades. All studies conducted solely in the intensive care population were conducted after 2006 and a vast majority in the last 10 years.

We could not sufficiently explain the heterogeneity in the primary outcome using the quality of the studies. Insufficient reporting affected the risk of bias and applicability-related concerns negatively. The high risk of bias for the domain 'outcomes' was typically associated with a higher percentage of admissions with an AE. Sauro *et al*²³ reported, in accordance with our findings, a significantly higher pooled estimate of AEs for lower-quality studies. Furthermore, they showed, in consistency with the current study, that the presence of AEs at admission was unclear.

Many methodological limitations and reasons for the variations of AE outcomes in published studies have been suggested, for example, patient record documentation, the experience of the review team, quality assurance activities, inclusion criteria, AE definitions, choice of triggers and time frame for inclusion of AEs. Apart from the researchers' adaptations, some variations may be explained by the different record review methods. Although, it would have been very interesting to analyse the variation based on the different methodological applications, it was outside of the scope of this review. In a recently published meta-analysis for adult inpatients, some of the variation could be explained by those methodological aspects (type of hospital included, age of sample included and experience of the review team).²⁹

Another aspect is that variables that might affect the estimates of AE outcomes were not always clearly specified in the studies, for example, the time frames for AE inclusion. As a consequence, data extractors made interpretations based on triggers, for example, hospital readmission within 30 days. Another example is the inclusion of acts of commissions and/or omissions which was often not explicitly specified in the studies. GTT and TT studies following the Institute for Healthcare Improvement's manual exclude AEs related to acts of omission which could lead to an underestimation of AEs. Wilson et al^{12} found in their study that acts of omission were nearly twice as common as acts of commission. Hibbert *et al*⁶ suggest that several additional variables should be included when using GTT, for example, omissions, preventability and other characterisations, to get a better understanding of AEs. This suggestion is in accordance with the HMPS methodology, where AEs are categorised to a higher extent compared with GTT. To summarise, as many studies use minor adaptations of the record review process,^{19 80} the reporting of AEs would benefit from a standardised guideline. This would decrease the methodological heterogeneity, thereby increasing replicability, interpretations and comparisons.

Clinical implications

Despite variations between inpatient care, AE outcomes and measurements, the high incidence of AEs and

percentage of preventable AEs indicate that there is more to be done regarding patient safety interventions. Zegers et al⁸¹ made an umbrella review concerning evidence-based interventions to reduce inpatient AEs and they conclude a need for more high-quality studies to determine what interventions will have the most positive impact on patient safety. However, they state that there is evidence available for interventions to prevent infections, falls, delirium, adverse drug events, cardiopulmonary arrest and mortality. Furthermore, the measurement of AEs must be incorporated as part of the learning system within healthcare organisations and be connected to evidence-based interventions and evaluation of these as part of the continuous improvement work as measurement alone does not create safe care.⁸²

Strengths and limitations

The adoption of a robust search strategy using several databases with no limitations in publication dates or language of publication lessens the likelihood that important studies were missed and may have changed the estimates in a significant way. However, the possibility of missing potentially relevant studies meeting the inclusion criteria is always present as we did not search for 'grey' literature. We did not use funnel plots to explore publication bias or other biases associated with small study size, as patterns of publication bias in the field of single-arm studies reporting proportions is not well understood and also because funnel plot analyses can lead to inaccurate conclusions.⁸³A rigorous approach was adopted to the screening and data extraction process, as well as the assessment of bias and applicability. The large number of studies included further strengthens the study. We also contacted the authors for several of the studies where vital variables were missing. This led to fewer variables being categorised as not specified and therefore fewer studies were excluded from the meta-analyses.

One limitation is that the exclusion criteria disqualified studies with, for example, only automated AE detection, those including only outpatients or studies focusing on a specific diagnosis, treatment, or AE such as adverse drug events. This could have reduced the number of eligible studies and the final sample size as estimates could differ from estimates in a wider population. Concerning generalisability, most studies were conducted in Europe, as well as North and South America. Last but not the least, critically ill patients need complex care, which puts them at risk for AEs.³ As previously stated, paediatric patients run a high risk for AEs during inpatient care, in general care, but specifically in intensive care.⁷ Some of the heterogeneity within the general care population might be explained by the fact that several studies in the general care population also included intensive care patients to some extent. We choose to include a heterogeneous group of studies to provide estimates of paediatric

inpatient AEs to represent the diversity of hospital settings, as well as to include the three most common record review methodologies.

For the reporting of the meta-analysis, we have taken the decision to not report on I² values. This measure can be used to compare statistical heterogeneity but not clinical heterogeneity.⁸⁴ Rücker *et al*⁸⁴ recommends using τ^2 to assess clinical heterogeneity. IntHout *et al*³⁴ go a step further and recommend presenting PIs instead, as it is presented on the same scale as the outcome measure in contrast to τ^2 or I². Therefore, we opted to provide PIs as measures of heterogeneity.

We acknowledge a deviation from the published study protocol, as we changed our primary outcome measure during the data-extraction phase, before conducting any statistical analyses. The percentage of admissions with ≥ 1 AE was chosen instead of AEs per 100 admissions, because this was the only measure with which we could directly compare the two methodological groups of GTT/TT and HMPS.

CONCLUSION

This review demonstrates a large between-study variation in estimates of the incidence of paediatric AEs. It also highlights the importance of a thorough understanding of the complex nature of AEs, and the sources of variation and of bias. The current lack of reporting standards in this field impedes comparison of study results. To advance the field of record review methodology, new reporting and risk of bias guidance tools are needed to enhance both comparability and overall quality of the studies and to maximise impact of study findings.

Author affiliations

¹Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

²Division of Pediatrics, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

³Institute of Nursing Science, Department Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland

⁴Department of Medical and Surgical Sciences SMECHIMAI, University of Modena and Reggio Emilia, Modena, Italy

⁵Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

⁶School of Health and Welfare, Dalarna University, Falun, Sweden

⁷Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ⁸Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland

⁹Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden

Twitter Luisa C Eggenschwiler @l_eggens, Anne W S Rutjes @AnneRutjes and Michael Simon @msimoninfo

Acknowledgements The authors wish to thank the librarians Alena Lindfors, Ulrika Gabrielsson and Kristina Lönn at Dalarna University for support with the development and tests of search strategies as well as the performance of the database searches. The authors would also like to thank Paula Kelly-Pettersson for the editing of this manuscript. An acknowledgement also to the ones who provided supplemental data for the data analyses: Swati Agarwal, Ross Baker, Laura Barrionuevo, Troyen Brennan, Peter Davis, Sana El Mhamdi, María Eugenia Esandi, Virginia Flintoft, Robert Giddered, Stephen Hancock, Facundo Jorro Barón, Alexander Kiss, Gitte Larsen, Roy Lay-Yee, Lucian Leape, Mondher Letaief, Anne Matlow, Geetanjali Shankarprasad Salimath, Stephan Schug, Paul Sharek, Anne Lee Solevåg, Michael Soop, Carin Verlaat and Jentien Vermeulen.

Contributors PD, LCE, AWSR, LB, SNM, MS, UF and MU contributed to conceptualisation of the project and to methodology. PD, LCE and MU carried out data curation. LCE performed formal analysis with support from AWSR and GM. PD, LCE, UF and MU wrote the original draft. All authors contributed to review and editing of the manuscript. PD and LCE contributed equally to this paper. Author responsible for the overall content is MU.

Funding This study was funded by grants from a regional agreement on clinical research (ALF) between Region Stockholm and Karolinska Institutet (2020-0443), Childhood Foundation of the Swedish Order of Freemasons (no award/ grant number).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. Data and R code are available on 10.5281/ zenodo.7335611.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4. 0/.

ORCID iDs

Pernilla Dillner http://orcid.org/0000-0001-7350-7572 Luisa C Eggenschwiler http://orcid.org/0000-0002-1939-2345 Anne W S Rutjes http://orcid.org/0000-0001-9782-779X Lena Berg http://orcid.org/0000-0003-1815-799X Sarah N Musy http://orcid.org/0000-0003-0267-3375 Michael Simon http://orcid.org/0000-0003-2349-7219 Giusi Moffa http://orcid.org/0000-0002-2739-0454 Ulrika Förberg http://orcid.org/0000-0003-4291-425X Maria Unbeck http://orcid.org/0000-0002-5090-0352

REFERENCES

- 1 Tessier L, Guilcher SJT, Bai YQ, *et al.* The impact of hospital harm on length of stay, costs of care and length of person-centred episodes of care: a retrospective cohort study. *CMAJ* 2019;191:E879–85.
- 2 Lanzillotti LdaS, De Seta MH, de Andrade CLT, *et al.* Adverse events and other incidents in neonatal intensive care units. *Cien Saude Colet* 2015;20:937–46.
- 3 Kohn LT, Corrigan JM, Donaldson MS. *To err is human: building a safer health system*. Washington (DC): Institute of

Medicine Committee on Quality of Health Care in, America, 1999.

- 4 World Health Organisation. World Alliance for patient safety: forward programme 2005 France, 2004. Available: https:// apps.who.int/iris/handle/10665/43072
- 5 Griffin F, Resar R. *IHI global trigger tool for measuring adverse events (second edition*. Cambridge, Massachusetts: Instutute for Healthcare Improvment, 2009.
- 6 Hibbert PD, Molloy CJ, Hooper TD, *et al*. The application of the global trigger tool: a systematic review. *Int J Qual Health Care* 2016;28:640–9.
- 7 Kalisch BJ, Landstrom G, Williams RA. Missed nursing care: errors of omission. *Nurs Outlook* 2009;57:3–9.
- 8 Larsen GY, Donaldson AE, Parker HB, *et al*. Preventable harm occurring to critically ill children. *Pediatr Crit Care Med* 2007;8:331–6.
- 9 Valentin A, Capuzzo M, Guidet B, et al. Patient safety in intensive care: results from the multinational sentinel events evaluation (see) study. Intensive Care Med 2006;32:1591–8.
- 10 Murff HJ, Patel VL, Hripcsak G, *et al.* Detecting adverse events for patient safety research: a review of current methodologies. *J Biomed Inform* 2003;36:131–43.
- 11 Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard medical practice study I. N Engl J Med 1991;324:370–6.
- 12 Wilson RM, Runciman WB, Gibberd RW, et al. The quality in Australian health care study. Med J Aust 1995;163:458–71.
- 13 Landrigan CP, Stockwell D, Toomey SL, et al. Performance of the global assessment of pediatric patient safety (GAPPS) tool. *Pediatrics* 2016;137:06.
- 14 Unbeck M, Lindemalm S, Nydert P, *et al.* Validation of triggers and development of a pediatric trigger tool to identify adverse events. *BMC Health Serv Res* 2014;14:655.
- 15 Mattsson TO, Knudsen JL, Brixen K, et al. Does adding an appended oncology module to the global trigger tool increase its value? Int J Qual Health Care 2014;26:553–60.
- 16 Nilsson L, Borgstedt-Risberg M, Brunner C, et al. Adverse events in psychiatry: a national cohort study in Sweden with a unique psychiatric trigger tool. BMC Psychiatry 2020;20:44.
- 17 Lindblad M, Schildmeijer K, Nilsson L, et al. Development of a trigger tool to identify adverse events and no-harm incidents that affect patients admitted to home healthcare. BMJ Qual Saf 2018;27:502–11.
- 18 Classen DC, Resar R, Griffin F, *et al.* 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. *Health Aff* 2011;30:581–9.
- 19 Klein DO, Rennenberg RJMW, Koopmans RP, et al. A systematic review of methods for medical record analysis to detect adverse events in hospitalized patients. J Patient Saf 2021;17:e1234–40.
- 20 Naessens JM, Campbell CR, Huddleston JM, et al. A comparison of hospital adverse events identified by three widely used detection methods. Int J Qual Health Care 2009;21:301–7.
- 21 de Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care 2008;17:216–23.
- 22 Panagioti M, Khan K, Keers RN, *et al.* Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysis. *BMJ* 2019;366:l4185.

- 23 Sauro KM, Machan M, Whalen-Browne L, *et al*. Evolving factors in hospital safety: a systematic review and meta-analysis of hospital adverse events. *J Patient Saf* 2021;17:e1285–95.
- 24 Schwendimann R, Blatter C, Dhaini S, et al. The occurrence, types, consequences and preventability of in-hospital adverse events - a scoping review. BMC Health Serv Res 2018;18:521.
- 25 Berchialla P, Scaioli G, Passi S, et al. Adverse events in hospitalized paediatric patients: a systematic review and a meta-regression analysis. J Eval Clin Pract 2014;20:551–8.
- 26 Bramer WM, Rethlefsen ML, Kleijnen J, et al. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev 2017;6:245.
- 27 Whiting PF, Rutjes AWS, Westwood ME, *et al.* QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529–36.
- 28 Musy SN, Ausserhofer D, Schwendimann R, et al. Trigger Tool-Based automated adverse event detection in electronic health records: systematic review. J Med Internet Res 2018;20:e198.
- 29 Eggenschwiler LC, Rutjes AWS, Musy SN, et al. Variation in detected adverse events using trigger tools: a systematic review and meta-analysis. PLoS One 2022;17:e0273800.
- 30 R Core Team. R:A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing, 2022. Available: https://www.R-project.org/
- 31 Balduzzi S, Rücker G, Schwarzer G. How to perform a metaanalysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22:153–60.
- 32 Viechtbauer W. Conducting meta-analyses in R with the metafor package. JSS 2010;36:1–48.
- 33 Zegers M, de Bruijne MC, Wagner C, *et al*. Adverse events and potentially preventable deaths in Dutch hospitals: results of a retrospective patient record review study. *Qual Saf Health Care* 2009;18:297–302.
- 34 IntHout J, Ioannidis JPA, Rovers MM, et al. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016;6:e010247.
- 35 Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011;342:d549.
- 36 Harbord RM, Deeks JJ, Egger M, et al. A unification of models for meta-analysis of diagnostic accuracy studies. *Biostatistics* 2007;8:239–51.
- 37 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- 38 Agarwal S, Classen D, Larsen G, et al. Prevalence of adverse events in pediatric intensive care units in the United States. *Pediatr Crit Care Med* 2010;11:568–78.
- 39 Barrionuevo LS, Esandi ME. [Epidemiology of adverse events in the neonatal unit of a regional public hospital in Argentina]. *Arch Argent Pediatr* 2010;108:303–10.
- 40 Chapman SM, Fitzsimons J, Davey N, et al. Prevalence and severity of patient harm in a sample of UK-hospitalised children detected by the paediatric trigger tool. BMJ Open 2014;4:e005066.
- 41 Davenport MC, Domínguez PA, Ferreira JP, *et al.* Measuring adverse events in pediatric inpatients with the global trigger tool. *Arch Argent Pediatr* 2017;115:357–63.
- 42 Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals I: occurrence and impact. N Z Med J 2002;115:U271.

- 43 Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals II: preventability and clinical context. N Z Med J 2003;116:U624.
- 44 Davis P, Lay-Yee R, Briant R. Adverse events on new Zealand public hospitals: principal findings from a national survey. Occasional Paper No 3: Wellington: Ministry of Health, 2001.
- 45 Fajreldines A, Schnitzler E, Torres S, *et al.* Measurement of the incidence of care-associated adverse events at the Department of pediatrics of a teaching hospital. *Arch Argent Pediatr* 2019;117:e106–9.
- 46 Geetanjali S, Ganachari MS. Development of a pediatric focused trigger tool to assess the prevalence of adverse events at a hospital setting: a retrospective structured chart review. *IJPR* 2020;12:1387–98.
- 47 Hiatt HH, Barnes BA, Brennan TA, et al. A study of medical injury and medical malpractice. N Engl J Med 1989;321:480–4.
- 48 Hooper AJ, Tibballs J. Comparison of a trigger tool and voluntary reporting to identify adverse events in a paediatric intensive care unit. *Anaesth Intensive Care* 2014;42:199–206.
- 49 Jorro-Barón F, Suarez-Anzorena I, Burgos-Pratx R, *et al.* Handoff improvement and adverse event reduction programme implementation in paediatric intensive care units in Argentina: a stepped-wedge trial. *BMJ Qual Saf* 2021;30:782–91.
- 50 Kirkendall ES, Kloppenborg E, Papp J, *et al.* Measuring adverse events and levels of harm in pediatric inpatients with the global trigger tool. *Pediatrics* 2012;130:e1206–14.
- 51 Lander L, Roberson DW, Plummer KM, et al. A trigger tool fails to identify serious errors and adverse events in pediatric otolaryngology. Otolaryngol Head Neck Surg 2010;143:480–6.
- 52 Leape LL, Brennan TA, Laird N, *et al.* The nature of adverse events in hospitalized patients. Results of the Harvard medical practice study II. *N Engl J Med* 1991;324:377–84.
- 53 Letaief M, El Mhamdi S, El-Asady R, et al. Adverse events in a Tunisian Hospital: results of a retrospective cohort study. Int J Qual Health Care 2010;22:380–5.
- 54 Matlow A, Flintoft V, Orrbine E, et al. The development of the Canadian paediatric trigger tool for identifying potential adverse events. *Healthc Q* 2005;8 Spec No:90–3.
- 55 Matlow AG, Baker GR, Flintoft V, *et al.* Adverse events among children in Canadian hospitals: the Canadian paediatric adverse events study. *CMAJ* 2012;184:E709–18.
- 56 Matlow AG, Cronin CMG, Flintoft V, et al. Description of the development and validation of the Canadian paediatric trigger tool. BMJ Qual Saf 2011;20:416–23.
- 57 Maziero ECS, Cruz EDdeA, Alpendre FT, et al. Association between nursing work conditions and adverse events in neonatal and pediatric intensive care units. *Rev Esc Enferm* USP 2020;54:e03623.
- 58 Paredes Esteban RM, Garrido Pérez JI, Ruiz Palomino A, et al. [Implementation of a Plan of Patient Safety in Service of Pediatric Surgery. First results]. Cir Pediatr 2015;28:111–7.
- 59 Requena J, Miralles JJ, Mollar J. Clinical safety paediatric patients. *RCA* 2011;26:353–8.
- 60 Salimath GS, Ganachari MS, Gudhoor M. Paediatric focused triggering tool (PFTT) to assess the harm and its utilization to minimize the levels of harm among children at a tertiary care hospital. *IJPER* 2020;54:819–25.
- 61 Shah RK, Lander L, Forbes P, *et al.* Safety on an inpatient pediatric otolaryngology service: many small errors, few adverse events. *Laryngoscope* 2009;119:871–9.

- 62 Sharek PJ, Horbar JD, Mason W, *et al.* Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. *Pediatrics* 2006;118:1332–40.
- 63 Solevåg AL, Nakstad B. Utility of a paediatric trigger tool in a Norwegian department of paediatric and adolescent medicine. *BMJ Open* 2014;4:e005011.
- 64 Sommella L, de Waure C, Ferriero AM, *et al.* The incidence of adverse events in an Italian acute care Hospital: findings of a two-stage method in a retrospective cohort study. *BMC Health Serv Res* 2014;14:358.
- 65 Soop M, Fryksmark U, Köster M, *et al.* The incidence of adverse events in Swedish hospitals: a retrospective medical record review study. *Int J Qual Health Care* 2009;21:285–91.
- 66 Stockwell DC, Bisarya H, Classen DC, et al. A trigger tool to detect harm in pediatric inpatient settings. *Pediatrics* 2015;135:1036–42.
- 67 Stockwell DC, Landrigan CP, Toomey SL, *et al*. Adverse events in hospitalized pediatric patients. *Pediatrics* 2018;142:08.
- 68 Stroupe LM, Patra KP, Dai Z, et al. Measuring harm in hospitalized children via a trigger tool. J Pediatr Nurs 2018;41:9–15.
- 69 Thomas EJ, Orav EJ, Brennan TA. Hospital ownership and preventable adverse events. *Int J Health Serv* 2000;30:745–61.
- 70 Thomas EJ, Studdert DM, Burstin HR, *et al.* Incidence and types of adverse events and negligent care in Utah and Colorado. *Med Care* 2000;38:261–71.
- 71 Ventura CMU, Alves JGB, Meneses JdoA. [Adverse events in a Neonatal Intensive Care Unit]. *Rev Bras Enferm* 2012;65:49–55.
- 72 Verlaat CW, van der Starre C, Hazelzet JA, et al. The occurrence of adverse events in low-risk non-survivors in pediatric intensive care patients: an exploratory study. Eur J Pediatr 2018;177:1351–8.
- 73 Vermeulen JM, van Dijk M, van der Starre C, et al. Patient safety in South Africa: PICU adverse event registration*. *Pediatr Crit Care Med* 2014;15:464–70.

- 74 Woods D, Thomas E, Holl J, et al. Adverse events and preventable adverse events in children. *Pediatrics* 2005;115:155–60.
- 75 Zegers M, de Bruijne MC, Wagner C, *et al.* Design of a retrospective patient record study on the occurrence of adverse events among patients in Dutch hospitals. *BMC Health Serv Res* 2007;7:27.
- 76 Connolly W, Li B, Conroy R, *et al.* National and institutional trends in adverse events over time: a systematic review and meta-analysis of longitudinal retrospective patient record review studies. *J Patient Saf* 2021;17:141–8.
- 77 Baines RJ, Langelaan M, de Bruijne MC, et al. Changes in adverse event rates in hospitals over time: a longitudinal retrospective patient record review study. BMJ Qual Saf 2013;22:290–8.
- 78 Morillo-García Áurea, Aldana-Espinal JM, Olry de Labry-Lima A, *et al*. Hospital costs associated with nosocomial infections in a pediatric intensive care unit. *Gac Sanit* 2015;29:282–7.
- 79 Tang YH, Jeng MJ, Wang HH. Risk factors and predictive markers for early and late onset neonatal bacteremic sepsis in preterm and term infants. *J Chin Med Assoc* 2021.
- 80 Doupi P, Svaar H, Bjørn B, et al. Use of the global trigger tool in patient safety improvement efforts: Nordic experiences. Cogn Technol Work 2015;17:45–54.
- 81 Zegers M, Hesselink G, Geense W, et al. Evidence-Based interventions to reduce adverse events in hospitals: a systematic review of systematic reviews. BMJ Open 2016;6:e012555.
- 82 Sauro K, Ghali WA, Stelfox HT. Measuring safety of healthcare: an exercise in futility? *BMJ Qual Saf* 2020;29:341–4.
- 83 Hunter JP, Saratzis A, Sutton AJ, *et al*. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol* 2014;67:897–903.
- 84 Rücker G, Schwarzer G, Carpenter JR, et al. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008;8:79.